Babbage from The Economist

Coal is the dirtiest fossil fuel, bad for both the environment and human health. But it still produces a third of the world’s electricity. Eliminating its use will be crucial in the fight against climate change but the task is proving very challenging. As world leaders gather in Azerbaijan this week for the UN’s COP29 climate summit, we travel to South Africa to learn how to (and how not to) phase out coal. We also hear about the issues making waves at COP29—including what Donald Trump’s second presidential term could mean for climate change policy around the world.Host: Alok Jha, The Economist’s science and technology editor. Contributors: The Economist’s Vijay Vaitheeswaran, Rachel Dobbs and John McDermott.For more on COP29, check out the latest episode of our “Money Talks” podcast, which examines whether the bill for the energy transition has been overestimated.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Diagnoses of attention-deficit hyperactivity disorder (ADHD) are on the rise around the world. ADHD has traditionally been treated as a dysfunction in the brain, which leads to a range of symptoms that need to be fixed or mitigated, sometimes with medication. But the scientific evidence for that view is beginning to fray. A growing number of experts think that ADHD may simply represent another part of the spectrum of neurodiversity—a different way of being normal. This week, we explore the science underlying this view and the consequences it could have for the way in which the condition could be managed. Is it time to re-think ADHD? Host: Alok Jha, The Economist’s science and technology editor. Contributors: Duncan Astle of the University of Cambridge; and The Economist’s Slavea Chankova and Rachel Dobbs.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

The family of weight-loss jabs known as GLP-1 agonists are among pharma’s biggest blockbusters. But drugs like Ozempic have the potential to do much more than tackle diabetes and obesity. They have been found to treat cardiovascular and kidney disease, and they are also being tested for liver disease, Alzheimer’s and even addiction. If they live up to their promise, GLP-1s are set to transform health care. How can one class of drug do so much?Host: Alok Jha, The Economist’s science and technology editor. Contributors: Caroline Messer, an endocrinologist in New York; Daniel Drucker of the University of Toronto; and The Economist’s Natasha Loder and Shailesh Chitnis. For more on this topic, listen to our podcast on the physiological and psychological causes of obesity—and why GLP-1 drugs could reshape the world.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

NASA’s multi-billion-dollar Europa Clipper spacecraft is on its way to Europa, one of Jupiter’s mysterious icy moons. The mission will investigate whether the moon, whose icy crust conceals a vast ocean of liquid water, might harbour the kind of environment suitable for alien life. In their search for life elsewhere, scientists have in recent years become much more interested in the outer solar system's icy moons, once considered too far from the Sun to plausibly support life. Europa Clipper is one of several probes heading to (or planned to travel to) those faraway worlds. Will they find signs that life could exist there?Host: Alok Jha, The Economist’s science and technology editor. Contributors: Michele Dougherty and her team at Imperial College London; Nathalie Cabrol of the SETI Institute and the author of “The Secret Life of the Universe”; and The Economist’s Tim Cross.For more on this topic, listen to our podcast on the European Space Agency’s JUICE mission and our interviews with exoplanet hunters Didier Queloz and Jessie Christiansen.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

The remarkable recent test flight of SpaceX’s Starship brought the world one step closer to a host of new possibilities beyond Earth (not least the colonisation of Mars). But as well as reducing the cost of sending stuff into space and opening up new business opportunities in Earth orbit, Starship will also play an important role in NASA’s plans to return to the Moon. Meanwhile, China has its own lunar ambitions, and a much simpler plan than America’s. Who will win this new space race?Host: Alok Jha, The Economist’s science and technology editor. Contributors: Kari Bingen of the Centre for Strategic and International Studies; The Economist’s Tim Cross, Oliver Morton and Paddy Stephens.For more on this topic, listen to our podcasts on who owns the Moon, the new space economy, and the lunar South Pole.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

It’s been a big year for artificial intelligence—sealed by winning the highest accolades in the scientific world: the Nobel prizes. The innovations that underlie machine learning were recognised in the physics prize. And one of the most important scientific applications of machine learning won the chemistry prize. In the award for physiology or medicine, meanwhile, the discovery of micro-RNAs offers hope for a new generation of therapeutics. In this episode, we examine the winning discoveries and investigate how they could transform the world.Host: Alok Jha, The Economist’s science and technology editor. Contributors: The Economist’s Natasha Loder, Geoff Carr and Emilie Steinmark.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

For half a century, the exponential increases in computing performance have powered the digital age. These gains were achieved by shrinking the components on computer chips, meaning that each new generation of semiconductor technology has been faster and more efficient than the last. But, with engineers now facing limits to how much further silicon chips can shrink, and ever-increasing demand thanks to the AI boom, chipmakers are having to get creative. What are the technical innovations they hope will keep the world’s AI ambitions on track?Host: Alok Jha, The Economist’s science and technology editor. Contributors: Shailesh Chitnis, The Economist’s global business correspondent; Eric Pop of Stanford University; David Patterson, professor emeritus of the University of California, Berkeley; and The Economist’s Rachana Shanbhogue.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.

Seeing, smelling and being in nature can directly improve your physical and mental health. We may know this intuitively but it is now also backed up by an emerging body of scientific  research. What are the benefits of a walk in the woods? Why does the scent from certain trees enhance cancer-fighting cells in the immune system? What does birdsong have to do with pain management? And what exactly are your houseplants doing for your microbiome?Alok Jha, The Economist’s science and technology editor, speaks to Kathy Willis, professor of biodiversity at the University of Oxford and author of “Good Nature: The New Science of How Nature Improves Our Health”.Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.